Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2011Modern Rheumatology

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis

View Full Paper
Ask AI
Bookmark
Share

Authors

YSYoshihito ShimaThe University of OsakaTTTetsuya TomitaYazaki (United States)TITaeko IshiiTohoku Medical and Pharmaceutical University Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shima et al. (2011) studied this question.

synapsesocial.com/papers/6a8a489cfce154801ccbec7bhttps://doi.org/10.3109/s10165-011-0416-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1SERUM CYTOKINES (IL-6, TNF-α, IL-1β AND IFN-γ) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWEEN SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITY1994 · 338 citations
  2. 2Tocilizumab for the treatment of rheumatoid arthritis2010 · 93 citations
  3. 3Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy1996 · 72 citations
  4. 4Six‐month results of a double‐blind, placebo‐controlled trial of etanercept treatment in patients with active ankylosing spondylitis2003 · 470 citations